期刊
CIRCULATION RESEARCH
卷 95, 期 9, 页码 855-857出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/01.RES.0000146674.38319.07
关键词
-
资金
- NCI NIH HHS [P50CA90388, CA87879] Funding Source: Medline
- NHLBI NIH HHS [P50HL67665, HL66027] Funding Source: Medline
Platelet factor-4 (PF-4)/CXCL4 was the first chemokine described to inhibit neovascularization. Here, the product of the nonallelic variant gene of CXCL4, PF-4(var1)/PF-4(alt), designated CXCL4L1, was isolated for the first time from thrombin-stimulated human platelets and purified to homogeneity. Although secreted CXCL4 and CXCL4L1 differ in only three amino acids, CXCL4L1 was more potent in inhibiting chemotaxis of human microvascular endothelial cells toward interleukin-8 (IL-8)/CXCL8 or basic fibroblast growth factor ( bFGF). In vivo, CXCL4L1 was also more effective than CXCL4 in inhibiting bFGF-induced angiogenesis in rat corneas. Thus, activated platelets release CXCL4L1, a potent regulator of endothelial cell biology, which affects angiogenesis and vascular diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据